STOCK TITAN

Advanced Biomed (NASDAQ: ADVB) investors approve all 2026 meeting proposals

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Advanced Biomed Inc. reported the results of its annual stockholder meeting held on June 30, 2026, where all five proposals passed. Stockholders elected five directors, approved executive compensation on a non-binding basis, and chose annual advisory votes on pay.

Holders of 1,422,573.80 common shares were represented, about 86.105% of the 1,652,133 shares outstanding and entitled to vote as of May 29, 2026, establishing a quorum. Stockholders also ratified WWC, P.C. as auditor for the fiscal year ending June 30, 2026, and approved a potential adjournment of the meeting if needed.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares represented at meeting 1,422,573.80 shares Common stock present in person or by proxy at June 30, 2026 meeting
Shares outstanding entitled to vote 1,652,133 shares Common stock issued, outstanding and entitled to vote as of May 29, 2026
Quorum percentage 86.105% Portion of entitled shares represented at the annual meeting
Votes for CEO director Xiaomin Chen 1,296,710.80 votes For votes in director election, with 49,755.00 against/withheld
Say-on-pay for votes 1,346,420.80 votes Non-binding advisory approval of named executive officer compensation
Auditor ratification for votes 1,422,573.80 votes Votes in favor of ratifying WWC, P.C. as auditor for fiscal year ending June 30, 2026
Say-on-pay frequency one-year votes 1,346,420.60 votes Votes favoring annual advisory votes on executive compensation
Adjournment proposal for votes 1,422,537.80 votes Votes approving potential adjournment to solicit additional proxies
non-binding, advisory basis regulatory
"To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
Say-on-Pay financial
"the compensation of the Company’s named executive officers as disclosed in the proxy statement (“Say-on-Pay”)."
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
Broker Non-Votes regulatory
"Abstentions | | Broker Non-Votes 1,346,420.80 | | 45.00 | | 0.00 | | 76,108.00"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"To ratify the appointment of WWC, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
quorum regulatory
"representing approximately 86.105% of the 1,652,133 shares ... and therefore constituting a quorum."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 00000 0001941029 0001941029 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

June 30, 2026

Date of Report (Date of earliest event reported)

 

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

 

Nevada   001-42548   87-2177170
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification Number)

 

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

 

886-6-3121716

(Registrant’s telephone number including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  Trading Symbol(s)   Name of each exchange on which registered
Common Stock   ADVB The Nasdaq Stock Market LLC

 

 

 

  

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 30, 2026, at 10:00 a.m. Eastern Time, Advanced Biomed Inc. (the “Company”) held its annual meeting of stockholders (the “Meeting”) at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan. Holders of 1,422,573.80 shares of the Company’s common stock were present in person or by proxy at the Meeting, representing approximately 86.105% of the 1,652,133 shares of common stock issued and outstanding and entitled to vote at the Meeting as of the close of business on May 29, 2026, the record date for the Meeting, and therefore constituting a quorum. Five proposals were submitted to the stockholders for consideration at the Meeting. Based on the final tabulation of votes, each director nominee was elected and each of the proposals was approved. The final voting results for each matter submitted to a vote at the Meeting are as follows:

 

Proposal 1: To elect the five (5) director nominees named below to serve on the Board of Directors until the next annual meeting of stockholders and until their respective successors are duly elected and qualified.

 

   For   Against / Withheld   Abstentions   Broker Non-Votes 
Xiaomin Chen   1,296,710.80    49,755.00    0.00    76,108.00 
Mingze Yin   1,346,466.80    0.00    0.00    76,107.00 
Jing Zhang   1,346,460.80    5.00    0.00    76,108.00 
Cheang I Kei   1,346,460.80    5.00    0.00    76,108.00 
Mingyue Cai   1,346,460.80    5.00    0.00    76,108.00 

 

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement (“Say-on-Pay”).

 

For  Against / Withheld  Abstentions  Broker Non-Votes
1,346,420.80  45.00  0.00  76,108.00

 

Proposal 3: To recommend, on a non-binding, advisory basis, the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. Frequency results:

 

One Year  Two Years  Three Years  Abstentions  Broker Non-Votes
1,346,420.60  0.00  45.20  0.00  76,108.00

 

Proposal 4: To ratify the appointment of WWC, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.

 

For  Against / Withheld  Abstentions  Broker Non-Votes
1,422,573.80  0.00  0.00  0.00

 

Proposal 5: To approve the adjournment of the Meeting, if necessary or appropriate, to solicit additional proxies in favor of any of the foregoing proposals.

 

For  Against / Withheld  Abstentions  Broker Non-Votes
1,422,537.80  34.00  1.00  1.00

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Advanced Biomed Inc.
     
Date: July 1, 2026 By: /s/ Xiaomin Chen
    Xiaomin Chen
    Chief Executive Officer, director and
Chairman of the Board

 

2

 

FAQ

What did Advanced Biomed Inc. (ADVB) shareholders approve at the 2026 annual meeting?

Shareholders approved all five proposals, including electing five directors, endorsing executive compensation, setting annual say-on-pay frequency, ratifying WWC, P.C. as auditor for the year ending June 30, 2026, and authorizing a potential adjournment of the meeting if necessary or appropriate.

How many Advanced Biomed (ADVB) shares were represented at the June 30, 2026 meeting?

A total of 1,422,573.80 common shares were present in person or by proxy. This represented approximately 86.105% of the 1,652,133 common shares issued, outstanding, and entitled to vote as of the May 29, 2026 record date for the annual meeting.

What say-on-pay decisions did Advanced Biomed (ADVB) investors make in 2026?

Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 1,346,420.80 votes for, 45.00 against or withheld, no abstentions, and 76,108.00 broker non-votes. They also recommended holding future advisory say-on-pay votes every one year.

Which auditor did Advanced Biomed Inc. (ADVB) shareholders ratify for fiscal 2026?

Shareholders ratified the appointment of WWC, P.C. as Advanced Biomed’s independent registered public accounting firm for the fiscal year ending June 30, 2026. The ratification received 1,422,573.80 votes for, with no votes against, no abstentions, and no broker non-votes reported.

What quorum was achieved at Advanced Biomed’s June 30, 2026 annual meeting?

The meeting achieved a quorum with 1,422,573.80 shares of common stock represented. This equaled roughly 86.105% of the 1,652,133 shares issued, outstanding, and entitled to vote as of the May 29, 2026 record date for the annual stockholder meeting.

How did Advanced Biomed (ADVB) shareholders vote on meeting adjournment authority?

Shareholders approved a proposal to permit adjournment of the meeting if necessary or appropriate to solicit additional proxies. The vote totals were 1,422,537.80 for, 34.00 against or withheld, 1.00 abstention, and 1.00 broker non-vote recorded on the adjournment question.

Filing Exhibits & Attachments

3 documents